
  
    
      
        Background_NNP
        Acute_NNP pain_NN has_VBZ been_VBN studied_VBN in_IN single_JJ dose_NN designs_NNS first_RB
        proposed_VBN by_IN Beecher_NNP and_CC colleagues_NNS [_NN 1_CD 2_CD ]_NN and_CC formalized_JJ
        by_IN Houde_NNP and_CC Wallenstein_NNP [_NN 3_CD ]_NN ._. The_DT problem_NN with_IN single_JJ
        trials_NNS is_VBZ that_IN while_IN they_PRP can_MD demonstrate_VB statistical_JJ
        superiority_NN of_IN analgesic_JJ over_IN placebo_NN ,_, variation_NN because_IN of_IN
        random_JJ chance_NN means_VBZ that_IN ,_, if_IN small_JJ ,_, they_PRP provide_VBP a_DT poor_JJ
        estimate_NN of_IN the_DT size_NN of_IN the_DT analgesic_JJ effect_NN [_NN 4_CD ]_NN ._.
        Combining_NNP results_NNS from_IN clinically_RB homogeneous_JJ trials_NNS in_IN a_DT
        meta-analysis_JJ gives_VBZ an_DT accurate_JJ estimate_NN of_IN the_DT extent_NN of_IN
        the_DT analgesic_JJ effect_NN when_WRB sufficient_JJ numbers_NNS of_IN patients_NNS
        have_VBP been_VBN randomized_JJ [_NN 4_CD 5_CD ]_NN ._.
        Clinical_NNP trials_NNS in_IN acute_JJ pain_NN normally_RB last_JJ four_CD to_TO six_CD
        hours_NNS ,_, because_IN that_DT is_VBZ the_DT duration_NN of_IN effect_NN for_IN most_JJS
        analgesics_NNS ,_, whether_IN injected_VBN or_CC as_IN tablets_NNS ,_, and_CC for_IN simple_JJ
        analgesics_NNS ,_, NSAIDs_NNP or_CC opioids_NNS ._. Meta-analysis_NNP in_IN acute_JJ pain_NN
        has_VBZ concentrated_VBN on_IN the_DT use_NN of_IN the_DT area_NN under_IN the_DT total_JJ
        pain_NN relief_NN versus_CC time_NN curve_NN (_( TOTPAR_NNP )_) ,_, dichotomized_JJ into_IN
        at_IN least_JJS 50_CD %_NN pain_NN relief_NN or_CC not_RB [_NN 6_CD ]_NN ._. It_PRP is_VBZ not_RB
        necessarily_RB the_DT only_JJ measure_NN available_JJ or_CC the_DT most_RBS
        relevant_JJ ._. The_DT precedent_NN exists_VBZ at_IN a_DT primary_JJ research_NN level_NN
        for_IN adopting_VBG remedication_NN as_IN an_DT outcome_NN ._. Bullingham_NNP and_CC
        colleagues_NNS [_NN 7_CD ]_NN and_CC Gibb_NNP and_CC colleagues_NNS [_NN 8_CD ]_NN explored_JJ the_DT
        measure_NN of_IN re-medication_JJ in_IN post-surgical_JJ patients_NNS subject_JJ
        to_TO multiple_JJ dosing_VBG ._. A_NNP '_POS rescue_NN factor_NN '_'' design_NN was_VBD refined_VBN to_TO
        demonstrate_VB both_DT analgesic_JJ efficacy_NN and_CC assay_NN sensitivity_NN ._.
        [_NN 9_CD ]_NN ._. Farrar_NNP and_CC colleagues_NNS [_NN 10_CD ]_NN extrapolated_VBN from_IN
        re-medication_JJ data_NNS in_IN an_DT effort_NN to_TO both_DT define_VB and_CC
        demonstrate_VB analgesic_JJ efficacy_NN ._.
        Despite_IN these_DT efforts_NNS ,_, time_NN to_TO remedication_NN has_VBZ never_RB
        become_VBN a_DT standard_JJ outcome_NN in_IN analgesic_JJ trials_NNS ._. One_CD reason_NN
        for_IN this_DT might_MD simply_RB be_VB the_DT similarity_NN in_IN duration_NN between_IN
        commonly_RB used_VBN analgesics_NNS ._. For_IN rofecoxib_NN ,_, this_DT might_MD be_VB
        different_JJ ._. In_IN arthritis_NN 12_CD ._. 5_LS mg_NN or_CC 25_CD mg_NN of_IN rofecoxib_NN is_VBZ
        given_VBN as_IN a_DT single_JJ dose_NN once_RB a_DT day_NN to_TO control_VB pain_NN ._. The_DT
        acute_JJ pain_NN dose_NN of_IN 50_CD mg_NN is_VBZ claimed_VBN to_TO have_VB prolonged_JJ
        analgesic_JJ activity_NN [_NN 11_CD ]_NN ._.
        The_DT purpose_NN of_IN this_DT systematic_JJ review_NN and_CC meta-analysis_JJ
        of_IN rofecoxib_NN in_IN acute_JJ pain_NN was_VBD threefold_RB ._. First_LS to_TO examine_VB
        all_DT acute_JJ pain_NN studies_NNS of_IN analgesic_JJ efficacy_NN in_IN adults_NNS over_IN
        six_CD hours_NNS for_IN comparison_NN with_IN other_JJ analgesics_NNS in_IN acute_JJ
        pain_NN ._. Second_JJ to_TO examine_VB the_DT amount_NN and_CC quality_NN of_IN the_DT
        evidence_NN presented_VBN on_IN extended_VBN duration_NN of_IN analgesia_NN ._. Third_NNP
        to_TO examine_VB the_DT quality_NN and_CC quantity_NN of_IN evidence_NN on_IN adverse_JJ
        events_NNS ._.
      
      
        Methods_NNP
        QUORUM_NNP guidelines_NNS were_VBD followed_VBN [_NN 12_CD ]_NN ._. Possible_JJ
        studies_NNS for_IN inclusion_NN were_VBD sought_VBN through_IN searching_VBG the_DT
        Cochrane_NNP Library_NNP (_( issue_NN 4_CD ,_, 2001_CD )_) ,_, Biological_NNP Abstracts_NNP
        (_( March_NNP 2002_CD )_) ,_, MEDLINE_NNP (_( March_NNP 2002_CD )_) and_CC PubMed_NNP (_( March_NNP 2002_CD )_)
        using_VBG rofecoxib_NN as_IN a_DT free_JJ text_NN term_NN ._. The_DT search_NN strategy_NN
        used_VBN is_VBZ detailed_VBN in_IN Additional_JJ File_NNP 1_CD ._. Abstracts_NNP were_VBD
        examined_VBN for_IN possible_JJ inclusion_NN if_IN they_PRP were_VBD randomized_JJ
        trials_NNS conducted_VBN in_IN an_DT acute_JJ pain_NN setting_NN ,_, used_VBN rofecoxib_NN
        and_CC a_DT placebo_NN or_CC active_JJ comparator_NN ._. Reference_NNP lists_NNS and_CC
        review_NN articles_NNS were_VBD examined_VBN for_IN possible_JJ additional_JJ
        references_NNS ,_, and_CC in-house_JJ databases_NNS were_VBD also_RB searched_VBD for_IN
        papers_NNS ._.
        Criteria_NNP for_IN inclusion_NN for_IN postoperative_JJ pain_NN were_VBD :_: full_JJ
        journal_NN publication_NN ,_, randomized_JJ controlled_VBN trials_NNS which_WDT
        included_VBD single_JJ dose_NN treatment_NN groups_NNS of_IN oral_JJ rofecoxib_NN and_CC
        placebo_NN ,_, double_JJ blind_JJ design_NN ,_, baseline_JJ postoperative_JJ pain_NN
        of_IN moderate_JJ to_TO severe_JJ intensity_NN ,_, patients_NNS over_IN 15_CD years_NNS of_IN
        age_NN ,_, at_IN least_JJS 10_CD patients_NNS per_IN group_NN ,_, and_CC the_DT pain_NN outcome_NN
        measures_NNS of_IN total_JJ pain_NN relief_NN (_( TOTPAR_NNP )_) or_CC summed_VBD pain_NN
        intensity_NN difference_NN (_( SPID_NNP )_) over_IN 4_CD -_: 6_CD hours_NNS or_CC sufficient_JJ
        data_NNS to_TO allow_VB their_PRP$ calculation_NN ._. Pain_NNP measures_NNS allowed_VBN for_IN
        the_DT calculation_NN of_IN TOTPAR_NNP or_CC SPID_NNP were_VBD a_DT standard_JJ five_CD
        point_NN pain_NN relief_NN scale_NN (_( none_NN ,_, slight_JJ ,_, moderate_JJ ,_, good_JJ ,_,
        complete_JJ )_) ,_, a_DT standard_JJ four_CD point_NN pain_NN intensity_NN scale_NN
        (_( none_NN ,_, mild_JJ ,_, moderate_JJ ,_, severe_JJ )_) or_CC a_DT standard_JJ visual_JJ
        analogue_NN scale_NN (_( VAS_NNP )_) for_IN pain_NN relief_NN or_CC pain_NN intensity_NN ._.
        Also_RB of_IN interest_NN was_VBD information_NN on_IN the_DT time_NN to_TO
        remedication_NN ._. For_IN adverse_JJ events_NNS ,_, the_DT primary_JJ outcome_NN
        sought_VBN was_VBD the_DT proportion_NN of_IN patients_NNS experiencing_VBG any_DT
        adverse_JJ event_NN ,_, with_IN secondary_JJ outcomes_NNS of_IN patients_NNS
        experiencing_VBG particular_JJ adverse_JJ events_NNS ._. Although_IN adverse_JJ
        events_NNS are_VBP often_RB reported_VBN inconsistently_RB in_IN acute_JJ pain_NN
        trials_NNS [_NN 13_CD ]_NN ,_, the_DT outcome_NN of_IN any_DT patient_NN experiencing_VBG any_DT
        adverse_JJ event_NN was_VBD the_DT least_JJS inconsistently_RB reported_VBD ._.
        Each_DT report_NN which_WDT could_MD possibly_RB be_VB described_VBN as_IN a_DT
        randomized_JJ controlled_VBN trial_NN was_VBD read_VBN independently_RB by_IN at_IN
        least_JJS three_CD authors_NNS and_CC scored_VBD using_VBG a_DT commonly-used_JJ three_CD
        item_NN ,_, 1_CD -_: 5_CD score_NN ,_, quality_NN scale_NN [_NN 14_CD ]_NN ._. Consensus_NNP was_VBD then_RB
        achieved_VBN ._. The_DT maximum_NN score_NN of_IN an_DT included_VBN study_NN was_VBD 5_CD and_CC
        the_DT minimum_JJ score_NN was_VBD 2_CD ._. Authors_NNP were_VBD not_RB blinded_JJ because_IN
        they_PRP already_RB knew_VBD the_DT literature_NN ._.
        For_IN each_DT trial_NN ,_, mean_VB TOTPAR_NNP ,_, SPID_NNP ,_, VASTOTPAR_NNP or_CC VASSPID_NNP
        values_NNS for_IN each_DT treatment_NN group_NN were_VBD converted_VBN to_TO
        %_NN maxTOTPAR_NN by_IN division_NN into_IN the_DT calculated_VBN maximum_NN value_NN [_NN
        15_CD ]_NN ._. The_DT proportion_NN of_IN patients_NNS in_IN each_DT treatment_NN group_NN
        who_WP achieved_VBD at_IN least_JJS 50_CD %_NN maxTOTPAR_NN was_VBD calculated_VBN using_VBG
        valid_JJ equations_NNS [_NN 16_CD 17_CD 18_CD ]_NN ._. The_DT number_NN of_IN patients_NNS
        randomized_JJ was_VBD taken_VBN as_IN the_DT basis_NN for_IN calculations_NNS ,_, to_TO
        produce_VB an_DT intention_NN to_TO treat_VB analysis_NN ._. The_DT number_NN of_IN
        patients_NNS with_IN at_IN least_JJS 50_CD %_NN maxTOTPAR_NN was_VBD then_RB used_VBN to_TO
        calculate_VB relative_JJ benefit_NN and_CC NNT_NNP for_IN rofecoxib_NN versus_CC
        placebo_NN ._. The_DT same_JJ methods_NNS were_VBD used_VBN for_IN adverse_JJ events_NNS ._.
        Relative_NNP benefit_NN and_CC relative_JJ risk_NN estimates_NNS were_VBD
        calculated_VBN with_IN 95_CD %_NN confidence_NN intervals_NNS using_VBG a_DT fixed_VBN
        effects_NNS model_NN [_NN 19_CD ]_NN ._. Heterogeneity_NNP tests_NNS were_VBD not_RB used_VBN as_IN
        they_PRP have_VBP previously_RB been_VBN shown_VBN to_TO be_VB unhelpful_JJ [_NN 20_CD 21_CD ]_NN ,_,
        though_IN homogeneity_NN was_VBD examined_VBN visually_RB [_NN 22_CD ]_NN ._.
        Publication_NNP bias_NN was_VBD not_RB assessed_VBN using_VBG funnel_VB plots_NNS as_IN
        these_DT tests_NNS have_VBP been_VBN shown_VBN to_TO be_VB unhelpful_JJ [_NN 23_CD 24_CD ]_NN ._. The_DT
        number_NN needed_VBN to_TO treat_VB or_CC harm_VB (_( NNT_NNP and_CC NNH_NNP )_) with_IN
        confidence_NN intervals_NNS was_VBD calculated_VBN by_IN the_DT method_NN of_IN Cook_NNP
        and_CC Sackett_NNP [_NN 25_CD ]_NN from_IN the_DT sum_NN of_IN all_DT events_NNS and_CC patients_NNS
        for_IN treatment_NN and_CC placebo_NN ._. Cumulative_NNP calculation_NN of_IN NNT_NNP [_NN
        5_CD ]_NN was_VBD performed_VBN by_IN adding_VBG studies_NNS by_IN year_NN of_IN publication_NN ,_,
        and_CC alphabetically_RB within_IN a_DT year_NN ._.
        Relative_NNP benefit_NN or_CC risk_NN was_VBD considered_VBN to_TO be_VB
        statistically_RB significant_JJ when_WRB the_DT 95_CD %_NN confidence_NN interval_NN
        did_VBD not_RB include_VB 1_CD ._. NNT_NNP or_CC NNH_NNP values_NNS were_VBD only_RB calculated_VBN
        when_WRB the_DT relative_JJ risk_NN or_CC benefit_NN was_VBD statistically_RB
        significant_JJ ,_, and_CC are_VBP reported_VBN with_IN the_DT 95_CD %_NN confidence_NN
        interval_NN ._. Calculations_NNP were_VBD performed_VBN using_VBG Microsoft_NNP Excel_NNP
        2001_CD on_IN a_DT Power_NNP Macintosh_NNP G_NNP 4_CD ._.
        Additional_JJ file_NN 1_CD
        Search_NNP strategy_NN
        Click_NNP here_RB for_IN file_NN
      
      
        Results_NNS
        
          At_IN least_JJS 50_CD %_NN pain_NN relief_NN
          All_DT five_CD trials_NNS gave_VBD or_CC allowed_VBD the_DT calculation_NN of_IN
          six-hour_JJ TOTPAR_NNP and_CC the_DT derivation_NN of_IN the_DT number_NN of_IN
          patients_NNS with_IN at_IN least_JJS 50_CD %_NN maxTOTPAR_NN ._. There_EX was_VBD good_JJ
          agreement_NN between_IN the_DT five_CD studies_NNS (_( Figure_NN 1_LS )_) ._. Overall_RB
          252_CD /_NN 464_CD patients_NNS (_( 54_CD %_NN )_) given_VBN rofecoxib_NN 50_CD mg_NN had_VBD at_IN least_JJS
          50_CD %_NN maxTOTPAR_NN over_IN six_CD hours_NNS ,_, compared_VBN with_IN 24_CD /_NN 211_CD
          patients_NNS (_( 11_CD %_NN )_) with_IN placebo_NN ._. The_DT NNT_NNP for_IN one_CD patient_NN to_TO
          have_VB at_IN least_JJS half_JJ pain_NN relief_NN over_IN six_CD hours_NNS was_VBD 2_CD ._. 3_CD
          (_( 2_CD ._. 0_CD to_TO 2_CD ._. 6_CD )_) (_( Table_NNP 1_LS )_) ._. Cumulative_NNP meta-analysis_JJ of_IN the_DT
          five_CD trials_NNS (_( Figure_NN 2_LS )_) shows_VBZ that_IN the_DT 95_CD %_NN confidence_NN
          interval_NN of_IN the_DT calculated_VBN NNT_NNP fell_VBD within_IN ±_NN 0_CD ._. 5_CD NNT_NNP of_IN
          the_DT overall_JJ mean_NN (_( 1_CD ._. 8_CD to_TO 2_CD ._. 8_CD )_) when_WRB 500_CD patients_NNS had_VBD been_VBN
          randomized_JJ ._.
        
        
          Remedication_NNP time_NN
          Onset_NNP of_IN analgesia_NN with_IN rofecoxib_NN 50_CD mg_NN appeared_VBD to_TO be_VB
          generally_RB the_DT same_JJ as_IN with_IN comparator_NN analgesics_NNS ._. Trials_NNP
          tried_VBD to_TO discourage_VB remedication_NN within_IN 90_CD minutes_NNS ,_, and_CC
          two_CD patients_NNS in_IN one_CD trial_NN were_VBD excluded_VBN because_IN they_PRP
          remedicated_JJ within_IN 90_CD minutes_NNS ,_, one_CD on_IN placebo_NN and_CC one_CD on_IN
          rofecoxib_NN 50_CD mg_NN [_NN 26_CD ]_NN ._. This_DT was_VBD not_RB reported_VBN
          consistently_RB (_( Additional_JJ File_NNP 3_LS )_) ._. The_DT percentage_NN of_IN
          patients_NNS remedicating_VBG within_IN two_CD hours_NNS was_VBD given_VBN in_IN one_CD
          study_NN [_NN 26_CD ]_NN ,_, and_CC within_IN 24_CD hours_NNS in_IN two_CD [_NN 11_CD 27_CD ]_NN ._.
          Only_RB one_CD study_NN (_( ._. (_( [_NN 27_CD ]_NN gave_VBD cumulative_JJ remedication_NN
          rates_NNS over_IN the_DT duration_NN of_IN the_DT study_NN ._. Median_JJ time_NN to_TO
          remedication_NN was_VBD given_VBN in_IN three_CD studies_NNS [_NN 11_CD 27_CD 28_CD ]_NN ,_,
          and_CC this_DT allowed_JJ the_DT calculation_NN of_IN a_DT mean_NN of_IN the_DT three_CD
          trials_NNS weighted_VBN by_IN the_DT number_NN of_IN patients_NNS ._. For_IN placebo_NN
          the_DT weighted_JJ mean_NN time_NN to_TO remedication_NN from_IN 126_CD patients_NNS
          in_IN three_CD trials_NNS was_VBD 1_CD ._. 9_CD hours_NNS ._. For_IN rofecoxib_NN 50_CD mg_NN the_DT
          weighted_JJ mean_NN time_NN to_TO remedication_NN from_IN 322_CD patients_NNS in_IN
          three_CD trials_NNS was_VBD 13_CD ._. 6_CD hours_NNS ._. For_IN ibuprofen_NN 400_CD mg_NN the_DT
          weighted_JJ mean_NN time_NN to_TO remedication_NN from_IN 97_CD patients_NNS in_IN
          two_CD trials_NNS was_VBD 7_CD ._. 4_CD hours_NNS ._.
        
        
          Adverse_JJ events_NNS
          Adverse_JJ events_NNS were_VBD not_RB reported_VBN consistently_RB (_(
          Additional_JJ File_NNP 3_LS )_) ._. Two_CD trials_NNS reported_VBD the_DT proportion_NN of_IN
          patients_NNS having_VBG any_DT adverse_JJ event_NN ._. An_DT adverse_JJ event_NN was_VBD
          reported_VBN by_IN 33_CD %_NN of_IN patients_NNS on_IN placebo_NN and_CC 28_CD %_NN of_IN those_DT
          on_IN rofecoxib_NN 50_CD mg_NN (_( not_RB significantly_RB different_JJ ,_, Table_NNP
          1_LS )_) ._. Nausea_NN and_CC vomiting_NN were_VBD reported_VBN separately_RB in_IN three_CD
          dental_JJ trials_NNS ,_, and_CC both_DT occurred_VBD significantly_RB less_RBR
          frequently_RB with_IN rofecoxib_NN 50_CD mg_NN than_IN with_IN placebo_NN (_( Table_NNP
          1_LS )_) ._. For_IN both_DT there_EX were_VBD negative_JJ numbers_NNS needed_VBN to_TO harm_VB
          (_( -_: 11_CD and_CC -_: 12_CD respectively_RB )_) ,_, showing_VBG that_IN for_IN every_DT 11_CD or_CC
          12_CD patients_NNS given_VBN rofecoxib_NN ,_, one_CD fewer_JJR was_VBD nauseous_JJ or_CC
          vomited_JJ than_IN with_IN placebo_NN ._. There_EX were_VBD few_JJ events_NNS ,_, though_RB ,_,
          with_IN only_RB 44_CD nauseated_JJ patients_NNS and_CC only_RB 27_CD who_WP vomited_JJ
          in_IN the_DT three_CD trials_NNS of_IN rofecoxib_NN 50_CD mg_NN comparable_JJ with_IN 34_CD
          nauseated_JJ patients_NNS and_CC only_RB 22_CD who_WP vomited_JJ in_IN the_DT two_CD
          trials_NNS of_IN ibuprofen_NN 400_CD mg_NN ._.
        
      
      
        Discussion_NNP
        The_DT five_CD included_VBD studies_NNS were_VBD of_IN generally_RB high_JJ
        reporting_NN quality_NN (_( quality_NN scores_NNS of_IN 4_CD or_CC 5_LS )_) ,_, known_VBN to_TO be_VB
        associated_VBN with_IN minimal_JJ reporting_NN bias_NN [_NN 30_CD 31_CD ]_NN ._. They_PRP all_DT
        had_VBD a_DT placebo_NN control_NN ,_, used_VBD standardized_JJ pain_NN intensity_NN and_CC
        relief_NN scores_NNS in_IN adult_NN patients_NNS with_IN established_VBN pain_NN of_IN
        moderate_JJ or_CC severe_JJ intensity_NN ,_, and_CC measured_VBD outcomes_NNS over_IN at_IN
        least_JJS six_CD hours_NNS ._. The_DT pain_NN models_NNS ,_, third_JJ molar_NN dental_JJ
        extraction_NN and_CC orthopaedic_JJ surgery_NN ,_, are_VBP commonly_RB used_VBN in_IN
        research_NN and_CC choice_NN of_IN model_NN does_VBZ not_RB appear_VB to_TO influence_VB
        results_NNS in_IN single-dose_JJ analgesic_JJ studies_NNS when_WRB patients_NNS are_VBP
        able_JJ to_TO take_VB oral_JJ medication_NN [_NN 13_CD ]_NN ._. Comparison_NNP of_IN
        rofecoxib_NN 50_CD mg_NN with_IN other_JJ analgesics_NNS over_IN six_CD hours_NNS is_VBZ
        legitimate_JJ ,_, because_IN the_DT same_JJ outcome_NN was_VBD measured_VBN in_IN the_DT
        same_JJ way_NN in_IN the_DT same_JJ patients_NNS over_IN the_DT same_JJ period_NN of_IN time_NN ,_,
        and_CC with_IN same_JJ comparator_NN ._.
        Compared_VBN with_IN placebo_NN ,_, the_DT NNT_NNP for_IN at_IN least_JJS 50_CD %_NN pain_NN
        relief_NN over_IN six_CD hours_NNS was_VBD 2_CD ._. 3_CD (_( 2_CD ._. 0_CD to_TO 2_CD ._. 6_CD )_) ._. Table_NNP 2_CD collects_VBZ
        NNTs_NNP for_IN a_DT number_NN of_IN common_JJ oral_JJ analgesics_NNS and_CC
        intramuscular_NN morphine_NN from_IN recent_JJ meta-analyses_JJ [_NN 32_CD 13_CD ]_NN
        and_CC unpublished_JJ updates_NNS of_IN other_JJ published_VBN Cochrane_NNP reviews_NNS
        [_NN 33_CD 34_CD ]_NN ._. Rofecoxib_NNP 50_CD mg_NN is_VBZ comparable_JJ with_IN other_JJ doses_NNS
        of_IN oral_JJ NSAIDs_NNP and_CC intramuscular_NN morphine_NN ._.
        For_IN rofecoxib_NN 50_CD mg_NN this_DT may_MD not_RB fully_RB reflect_VB its_PRP$
        efficacy_NN compared_VBN with_IN these_DT other_JJ analgesics_NNS ,_, because_IN
        rofecoxib_NN 50_CD mg_NN may_MD have_VB a_DT longer_JJR duration_NN of_IN action_NN ._. In_IN
        the_DT five_CD included_VBD trials_NNS duration_NN was_VBD inconsistently_RB
        reported_VBN ,_, however_RB ,_, with_IN median_JJ remedication_NN times_NNS in_IN three_CD
        trials_NNS (_( but_CC without_IN dispersion_NN )_) and_CC percentage_NN remedicated_JJ
        at_IN two_CD hours_NNS in_IN one_CD trial_NN and_CC 24_CD hours_NNS in_IN two_CD trials_NNS ._. This_DT
        disparity_NN in_IN reporting_VBG allowed_VBN only_RB the_DT crudest_JJS analysis_NN of_IN
        weighted_JJ mean_NN remedication_NN time_NN ._. This_DT was_VBD 1_CD ._. 9_CD hours_NNS for_IN
        placebo_NN ,_, 7_CD ._. 4_CD hours_NNS for_IN ibuprofen_NN 400_CD mg_NN and_CC 13_CD ._. 6_CD hours_NNS for_IN
        rofecoxib_NN 50_CD mg_NN ._. The_DT figures_NNS of_IN 7_CD ._. 4_CD hours_NNS for_IN ibuprofen_NN 400_CD
        mg_NN and_CC 1_CD ._. 9_CD hours_NNS for_IN placebo_NN is_VBZ in_IN agreement_NN with_IN a_DT larger_JJR
        unpublished_JJ analysis_NN (_( Barden_NNP et_CC al_NN ,_, unpublished_JJ
        observations_NNS )_) ._. The_DT extended_VBN time_NN to_TO remedication_NN for_IN
        rofecoxib_NN 50_CD mg_NN may_MD represent_VB a_DT real_JJ clinical_JJ advantage_NN
        where_WRB the_DT problem_NN is_VBZ not_RB a_DT lack_NN of_IN effective_JJ analgesics_NNS ,_,
        but_CC rather_RB effective_JJ analgesics_NNS ineffectively_RB delivered_VBN [_NN
        35_CD ]_NN ,_, and_CC given_VBN that_IN using_VBG a_DT relatively_RB large_JJ dose_NN has_VBZ no_DT
        disadvantages_NNS ._.
        The_DT efficacy_NN of_IN rofecoxib_NN in_IN these_DT five_CD classical_JJ
        clinical_JJ analgesic_JJ assays_NNS is_VBZ in_IN contrast_NN to_TO two_CD randomized_JJ
        comparisons_NNS of_IN rofecoxib_NN with_IN placebo_NN when_WRB given_VBN before_IN the_DT
        operation_NN in_IN adults_NNS [_NN 36_CD ]_NN and_CC children_NNS [_NN 37_CD ]_NN ._. The_DT
        methodological_JJ difficulties_NNS and_CC lack_NN of_IN effect_NN of_IN
        preemptive_JJ analgesia_NN have_VBP been_VBN pointed_VBN out_IN previously_RB [_NN 38_CD
        39_CD ]_NN ._. In_IN these_DT two_CD trials_NNS additional_JJ difficulties_NNS were_VBD the_DT
        large_JJ between-individual_JJ variation_NN in_IN morphine_NN consumption_NN
        in_IN adults_NNS [_NN 36_CD ]_NN ,_, and_CC the_DT use_NN of_IN a_DT novel_NN (_( unlicensed_JJ )_)
        syrup_NN formulation_NN of_IN rofecoxib_NN in_IN children_NNS [_NN 37_CD ]_NN ._. Lack_NN of_IN
        a_DT demonstrable_JJ analgesic_JJ effect_NN in_IN preemptive_JJ studies_NNS does_VBZ
        not_RB negate_NN a_DT substantial_JJ postoperative_JJ effect_NN when_WRB patients_NNS
        both_DT have_VBP pain_NN and_CC can_MD swallow_VB ._.
        There_EX was_VBD no_DT consistent_JJ pattern_NN of_IN adverse_JJ event_NN
        reporting_VBG in_IN the_DT five_CD included_VBD trials_NNS ._. Two_CD trials_NNS had_VBD
        information_NN on_IN any_DT patient_NN with_IN any_DT adverse_JJ event_NN (_( Table_NNP
        1_LS )_) ,_, with_IN no_DT difference_NN between_IN rofecoxib_NN 50_CD mg_NN and_CC placebo_NN ._.
        In_IN three_CD trials_NNS information_NN on_IN patients_NNS suffering_VBG nausea_NN
        and_CC vomiting_NN was_VBD available_JJ ,_, showing_VBG that_IN these_DT adverse_JJ
        events_NNS occurred_VBD less_RBR frequently_RB with_IN rofecoxib_NN 50_CD mg_NN than_IN
        placebo_NN ._. The_DT amount_NN of_IN information_NN (_( number_NN of_IN patients_NNS
        randomized_JJ )_) was_VBD insufficient_JJ to_TO make_VB any_DT authoritative_JJ
        statement_NN about_IN adverse_JJ events_NNS ,_, or_CC compare_VB the_DT adverse_JJ
        event_NN profile_NN of_IN rofecoxib_NN 50_CD mg_NN in_IN single_JJ doses_NNS with_IN other_JJ
        single_JJ dose_NN analgesics_NNS ._. Adverse_JJ events_NNS in_IN single-dose_JJ
        studies_NNS are_VBP often_RB poorly_RB reported_VBN ,_, and_CC of_IN limited_JJ value_NN [_NN
        40_CD ]_NN ._.
        In_IN clinical_JJ practice_NN ,_, NSAIDs_NNP are_VBP associated_VBN with_IN acute_JJ
        renal_JJ failure_NN in_IN patients_NNS with_IN impaired_VBN renal_JJ function_NN [_NN 41_CD
        42_CD ]_NN and_CC with_IN congestive_JJ heart_NN failure_NN in_IN older_JJR people_NNS with_IN
        a_DT prior_JJ history_NN of_IN heart_NN disease_NN [_NN 43_CD ]_NN ._. Acute_NNP renal_JJ
        failure_NN after_IN surgery_NN occurs_VBZ in_IN 1_CD patient_NN in_IN 1000_CD after_IN
        major_JJ surgery_NN [_NN 44_CD ]_NN ,_, though_IN it_PRP is_VBZ not_RB clear_JJ how_WRB much_JJ of_IN
        this_DT is_VBZ specifically_RB due_JJ to_TO the_DT NSAID_NNP ._. For_IN coxibs_NNS ,_,
        especially_RB at_IN high_JJ doses_NNS ,_, similar_JJ caution_NN should_MD be_VB used_VBN in_IN
        patients_NNS with_IN pre-existing_JJ renal_JJ or_CC cardiac_JJ conditions_NNS as_IN
        apply_VB to_TO the_DT use_NN of_IN NSAIDs_NNP ._. The_DT slope_NN of_IN the_DT adverse_JJ event_NN
        dose-response_JJ may_MD be_VB steeper_JJR than_IN for_IN analgesia_NN ._.
        These_DT published_VBN reports_NNS were_VBD insufficiently_RB detailed_JJ for_IN
        calculation_NN of_IN numbers_NNS needed_VBN to_TO treat_VB for_IN durations_NNS longer_JJR
        than_IN six_CD hours_NNS ._. Some_DT information_NN was_VBD available_JJ for_IN TOTPAR_NNP
        calculated_VBD to_TO eight_CD hours_NNS ,_, but_CC not_RB in_IN a_DT dichotomous_JJ format_NN ._.
        TOTPAR_NNP is_VBZ not_RB normally_RB distributed_VBN ,_, and_CC mean_VB values_NNS are_VBP not_RB
        meaningful_JJ [_NN 45_CD ]_NN ._. For_IN times_NNS longer_JJR than_IN six_CD hours_NNS ,_, and_CC
        for_IN duration_NN of_IN analgesia_NN and_CC adverse_JJ event_NN profiles_NNS ,_, more_RBR
        detailed_JJ information_NN from_IN individual_JJ patients_NNS would_MD be_VB
        required_VBN ._.
      
      
        Conclusions_NNP
        Rofecoxib_NNP at_IN a_DT dose_NN 2_CD -_: 4_CD times_NNS the_DT standard_JJ daily_JJ dose_NN
        for_IN chronic_JJ pain_NN is_VBZ an_DT effective_JJ single_JJ dose_NN oral_JJ analgesic_JJ
        in_IN acute_JJ pain_NN ._. Limitations_NNPS in_IN trial_NN reporting_VBG constrain_VB
        conclusions_NNS about_IN longer_JJR duration_NN of_IN analgesia_NN and_CC adverse_JJ
        event_NN profile_NN ._.
      
      
        Competing_VBG interests_NNS
        RAM_NNP has_VBZ been_VBN a_DT consultant_NN for_IN MSD_NNP ._. RAM_NNP &_CC HJM_NNP have_VBP
        consulted_VBN for_IN various_JJ pharmaceutical_JJ companies_NNS ._. RAM_NNP ,_, HJM_NNP
        &_CC JE_NNP have_VBP received_VBN lecture_NN fees_NNS from_IN pharmaceutical_JJ
        companies_NNS related_VBN to_TO analgesics_NNS and_CC other_JJ healthcare_NN
        interventions_NNS ._. All_DT authors_NNS have_VBP received_VBN research_NN support_NN
        from_IN charities_NNS ,_, government_NN and_CC industry_NN sources_NNS at_IN various_JJ
        times_NNS ,_, but_CC no_DT such_JJ support_NN was_VBD received_VBN for_IN this_DT work_NN ._. No_DT
        author_NN has_VBZ any_DT direct_JJ stock_NN holding_VBG in_IN any_DT pharmaceutical_JJ
        company_NN ._.
      
      
        Authors_NNP '_'' contributions_NNS
        JB_NNP was_VBD involved_VBN with_IN searching_VBG ,_, data_NNS extraction_NN ,_, quality_NN
        scoring_VBG ,_, analysis_NN and_CC writing_VBG ._. JE_NNP was_VBD involved_VBN with_IN
        searching_VBG ,_, data_NNS extraction_NN ,_, quality_NN scoring_VBG and_CC writing_VBG ._.
        HJM_NNP was_VBD involved_VBN in_IN analysis_NN and_CC writing_VBG ._. RAM_NNP was_VBD involved_VBN
        in_IN data_NNS extraction_NN ,_, quality_NN scoring_VBG ,_, analysis_NN and_CC
        writing_VBG ._.
      
    
  
